Revlimid (Celgene) meets endpoint for Multiple Myeloma
New data from a Phase III study (FIRST) of Revlimid (lenalidomide), from Celgene, in combination with dexamethasone in patients newly diagnosed with Multiple Myeloma, has met its primary endpoint. A total of 1,623 patients either beyond 65 years of age or not candidates for stem cell transplant were randomized into three arms: lenalidomide plus low-dose dexamethasone (Rd) (Arm A); Rd (Arm B); or melphalan, prednisone and thalidomide (Arm C).
After a median follow-up of 37 months, the trial met its primary endpoint (PFS), demonstrating a 28% reduction in risk of progression or death. The preplanned interim analysis of OS demonstrated a 22% reduction in risk of death in favor of Arm A vs. Arm C; however, the pre-specified boundary was not crossed. All other secondary endpoints consistently showed improvement in favour of Arm A vs. Arm C.
Main adverse events in Arm A vs. Arm C were neutropenia (28% vs. 45%), thrombocytopenia (8% vs. 11%), febrile neutropenia (1% vs. 3%) and infection (29% vs. 17%). Data were presented at the American Society of Hematology annual meeting.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins